SI
SCLN

Sensato Investors’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History

Sensato Investors’s Portfolio SCLN Stock Details SCLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-61,867
Closed -$606K – 96
2017
Q1 		$606K Sell
61,867
-367,202
-86% -$3.67M 0.1% 73
2016
Q4 		$4.63M Sell
429,069
-399,183
-48% -$3.99M 0.8% 40
2016
Q3 		$8.49M Sell
828,252
-286,986
-26% -$3.13M 1.8% 20
2016
Q2 		$14.6M Sell
1,115,238
-245,052
-18% -$3.21M 2.35% 13
2016
Q1 		$15M Sell
1,360,290
-28,799
-2% -$256K 2.66% 10
2015
Q4 		$12.8M Sell
1,389,089
-175,593
-11% -$1.47M 2.4% 18
2015
Q3 		$10.9M Sell
1,564,682
-205,100
-12% -$1.76M 2.03% 19
2015
Q2 		$17.4M Buy
1,769,782
+217,300
+14% +$1.98M 3.63% 7
2015
Q1 		$13.8M Buy
1,552,482
+172,020
+12% +$1.37M 2.96% 14
2014
Q4 		$12.1M Buy
+1,380,462
New +$11.2M 3.58% 11

Other funds holding SCLN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sensato Investors's SCLN Position: Q2 2017 in Review

Sensato Investors sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q2 2017, closing a stake of 61,867 shares — an estimated $606K sold.

Sensato Investors first reported a position in SCLN in Q4 2014 and held it in 10 quarters. The position peaked at $17.4M in Q2 2015. 142 funds tracked by Wall St. Rank hold SCLN as of Q2 2017.

  • Sensato Investors reported no remaining Sciclone Pharmaceuticals Inc position as of Q2 2017 after selling out during the quarter.
  • Sensato Investors sold 61,867 Sciclone Pharmaceuticals Inc shares in Q2 2017, an estimated $606K.
  • Sensato Investors first reported a position in Sciclone Pharmaceuticals Inc in Q4 2014 and held it in 10 quarters.
  • Sensato Investors's Sciclone Pharmaceuticals Inc position peaked at $17.4M in Q2 2015.
  • 142 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q2 2017.

Based on Sensato Investors's 13F filing for Q2 2017, filed 14 Aug 2017.